drugset / Trial / NCT01643759

Norspan Transdermal Patches Study in Osteoarthritis Patients

NCT01643759

Phase 1 Completed 30 enrolled Mundipharma (China) Pharmaceutical Co. Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a single center, open label, randomized, parallel group single dose pharmacokinetic (PK) study.

Timeline

Start
2009-07
Primary completion
2010-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 5 mg Other
Subject Buprenorphine Other / unclassified 10 mg Other
Subject Buprenorphine Other / unclassified 20 mg Other

Indications